Applying artificial intelligence (AI) to fragmented and incomplete safety data cannot fill the gap left when the right information has not been captured during initial
Alex will drive global commercial strategy and help scale Qinecsa’s next-generation pharmacovigilance technology across the life sciences ecosystem London, UK – January 12th, 2025 – Qinecsa, the
Qinecsa Chief Operating Officer, John Cogan, has been featured in Bio IT World latest issue, where he predicts trends in artificial intelligence, impact of global
Qinecsa Chief Operating Officer, John Cogan, has been featured in European Pharmaceutical Manufacturer latest issue, where he predicts where is the industry setting its sights for
Ongoing drug safety monitoring is critical to containing risk and keeping patients safe, and with so many channels for reporting adverse events, the workload in
Beena Wood, a drug safety specialist and chief product officer at Qinecsa Solutions, says 2025 has seen a reality check in this regard. In a pharmacovigilance
Beena Wood will build on the pure-bred pharmacovigilance specialist’s deep domain expertise and technology-powered solution portfolio to help reframe the contribution of drug safety London,
As the year comes to a close, Qinecsa reflects on a successful 2025 filled with global engagement and innovation in pharmacovigilance. Our team participated in key industry events across North
Qinecsa COO, John Cogan, has been featured in European Pharmaceutical Manufacturer‘s latest article, where he discusses AI’s relevance in powering the pharmacovigilance engine. As pharmacovigilance
Molecule to Market is a podcast focused on the pharmaceutical and biotech industries, particularly the outsourcing and supply chain side of drug development. Hosted by Raman
